Tampering with the genetic test results of tumor patients to defraud insurance, AstraZeneca 17 people fraud gang arrested

Shenzhen Medical Insurance Bureau reported that it once again punched AstraZeneca in the face

The details of the AstraZeneca fraud case have been officially announced, revealing two major points:

First, as many as 17 people were involved in the case, which was the nature of a fraud team, and 17 people had been arrested.

Second, the Health Insurance Bureau received a tip-off in July last year, much earlier than AstraZeneca claimed to have "voluntarily reported it after launching an internal compliance inspection in August."

On the evening of February 10, the Shenzhen Medical Insurance Bureau released a brief case report on the case of AstraZeneca staff suspected of defrauding the medical insurance fund. According to the circular, in July 2021, the Shenzhen Municipal Medical Insurance Bureau verified and found that AstraZeneca staff were suspected of fraud and insurance fraud based on the clues of the report, and then under the guidance of the National Medical Insurance Bureau, jointly with the Shenzhen Municipal Public Security Bureau and other relevant units to investigate the case.

After meticulous work, the case was successfully cracked, a fraud gang suspected of tampering with the genetic test results of tumor patients to defraud the medical insurance fund was smashed, 17 people involved in the case were arrested, and all criminal compulsory measures were taken in accordance with the law. At present, the case is under further investigation and handling.

The Health Bureau noted that the Shenzhen Medical Insurance Bureau "received a tip-off clue" in July, and AstraZeneca officially reported that in August 2021, during the internal compliance inspection, it was found that employees were suspected of insurance fraud and took the initiative to report to the Shenzhen Medical Insurance Bureau.

Obviously, it was the Shenzhen Medical Insurance Bureau that received the tip of the report first, and AstraZeneca's "internal compliance inspection" followed. Under such circumstances, does the "active reporting" argument still stand?

The insurance fraud case dealt a heavy blow to the Chinese market of AstraZeneca. On February 10, AstraZeneca and the head of the county team, He Shu, actually left his job and became one of the many executives who left AstraZeneca.

On February 10, AstraZeneca announced its fiscal 2021 annual report, and the fourth quarter of the China business fell by 4% year-on-year, the first decline in five years.

AstraZeneca, which has always been proud of the Chinese market, has shown a very rare decline. According to the FY21 annual report, AstraZeneca China's full-year revenue fell from US$1.362 billion in the same period of fiscal 2020 to US$1.312 billion, and its share of global revenue fell from 20% in 2020 to 16%.

Not only that, AstraZeneca also expects that revenue from its China business will also decline in single digits in the next fiscal year 2022.

AstraZeneca CEO Pascal Soriot admitted that AstraZeneca has encountered some headwinds in China.

The National Medical Insurance Bureau, in conjunction with the Ministry of Public Security and the National Health Commission, has carried out a nationwide special rectification of tampering with genetic test results to defraud medical insurance funds. In the document, the National Medical Insurance Bureau urged relevant enterprises and personnel to immediately surrender themselves if they had similar behavior.

#AstraZeneca ##骗保 #